CLPT

ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. It provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. It provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. It also offers IRRAflow active fluid-exchange system.

Wall Street analysts forecast CLPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLPT is 29.00 USD with a low forecast of 28.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Clearpoint Neuro Inc revenue for the last quarter amounts to 8.86M USD, increased 9.10 % YoY.

Clearpoint Neuro Inc. EPS for the last quarter amounts to -0.21 USD, increased 16.67 % YoY.

Clearpoint Neuro Inc (CLPT) has 115 emplpoyees as of December 16 2025.

Today CLPT has the market capitalization of 368.28M USD.